A study from the University of North Carolina Lineberger Comprehensive Cancer Center could help predict resistance to treatments for pancreatic cancer, one of the deadliest cancer types. In the journal Clinical Cancer Research, a journal of the American Association for Cancer Research, researchers led by UNC Lineberger’s Jen Jen Yeh, MD, and Naim Rashid, PhD, reported … Continued
In the journal Nature Communications, researchers from the University of North Carolina Lineberger Comprehensive Cancer Center reported they have designed a computational method for separating the different tissues in a particular sample – whether that is stroma in the case of pancreatic cancer, immune cells or cancer cells.
The University of North Carolina at Chapel Hill Integrated Translational Oncology Program (UNC-iTOP) is a T32 training program focused on training clinicians (MDs), basic scientists (PhDs), and PhD, MD and MD-PhD candidates in clinical/translational disease-based research at the interface of clinical oncology and cancer biology using patient samples.
We are thrilled to congratulate Matthew Lipner of Yeh lab on successfully completing his PhD defense, an achievement that follows years of hard work. A successful PhD defense is one of the landmark achievements of a researcher’s career and is sure to be only the first step in Matt’s journey.
The UNC School of Medicine has selected Jen Jen Yeh, MD, professor and vice chair of research for the department of surgery, and joint professor of pharmacology, for one of two annual awards in honor of Oliver Smithies, UNC’s first Nobel Prize winner.
To improve treatment and our understanding of one of the deadliest cancers in the United States, UNC Lineberger’s Jen Jen Yeh, MD, was involved in two studies that take different approaches to precision medicine for pancreatic cancer.
Richard Moffitt, a post-doctoral fellow in our group and now a tenure-track assistant professor at SUNY Stonybrook, led the mRNA and integrative analysis for the TCGA PAAD (pancreatic cancer) working group. The TCGA PAAD team performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma specimens, including samples with characteristic low neoplastic cellularity. … Continued